GTC Biotherapeutics, Ovation to collaborate over anti-coagulant

06/24/2008 | Forbes · Reuters

GTC Biotherapeutics has entered into a deal worth up to $257 million with Ovation Pharmaceuticals to develop and market ATryn, an experimental treatment for hereditary anti-thrombin deficiency, in the U.S. GTC could receive up to $9 million in milestone payments upon approval of the drug, which has obtained orphan designation and fast-track status from the FDA.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA